The pharmaceutical CDMO sector is at a crossroads, with AI-powered partnerships, geopolitical supply chain shifts, and a growing divide between specialised and integrated manufacturing redefining the industry. As Joon Ho Hwang, Vice President of Business Strategy at Samsung Biologics, notes, companies are increasingly integrating AI into drug discovery and manufacturing to reduce development timelines. Discover how these forces are reshaping pharmaceutical outsourcing.
The pharmaceutical CDMO sector is at a crossroads, with AI-powered partnerships, geopolitical supply chain shifts, and a growing divide between specialised and integrated manufacturing redefining the industry. As Joon Ho Hwang, Vice President of Business Strategy at Samsung Biologics, notes, companies are increasingly integrating AI into drug discovery and manufacturing to reduce development timelines. Discover how these forces are reshaping pharmaceutical outsourcing.
Share article
Related Content